Form 4: TELA Bio Director Guido Neels Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Guido Neels was granted restricted stock units and stock options as part of TELA Bio's equity incentive plan.
Summary
- Director Guido Neels acquired 11,925 restricted stock units (RSUs) vesting in three equal annual installments starting June 9, 2027.
- Director Guido Neels acquired 11,675 RSUs vesting on the earlier of June 9, 2027, the next annual meeting, or a change in control.
- Director Guido Neels was granted 17,550 stock options with an exercise price of $0.935, vesting in 36 equal monthly installments.
- Director Guido Neels was granted 17,335 stock options with an exercise price of $0.935, vesting on the earlier of June 9, 2027, the next annual meeting, or a change in control.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future shareholder dilution upon the exercise of stock options and vesting of RSUs.
Risks
- Continued service requirements for vesting create dependency on director retention.
- Market price volatility may impact the future value of granted equity.
Future Outlook
The equity grants are subject to continued service requirements, indicating a long-term retention strategy for the director.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the medical device sector to ensure board alignment with company performance.
Comparison to Industry Standards
- The use of a mix of RSUs and stock options is consistent with standard executive and director compensation packages in the small-cap healthcare industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Grant | Issuance of RSUs and stock options to Director Guido Neels under the 2019 Equity Incentive Plan. | 06/09/2026 | Increases director's equity stake in the company. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of RSUs beginning June 9, 2027.
- Monthly vesting of stock options starting July 9, 2026.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of earliest transaction and grant date for equity awards. |
| 06/11/2026 | Date of filing. |
| 06/09/2027 | Initial vesting date for restricted stock units and certain options. |
| 06/09/2036 | Expiration date for stock options. |
Keywords
TELA Bio, TELA, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.